MovDisordV3, PascalFrancis, Curation, bibRecord, 000384

Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: An exploratory case-control study

Identifieur interne : 000384 ( PascalFrancis/Curation ); précédent : 000383; suivant : 000385

Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: An exploratory case-control study

Auteurs : Maria D. Benedetti [États-Unis] ; Demetrius M. Maraganore [États-Unis] ; James H. Bower [États-Unis] ; Shannon K. Mcdonnell [États-Unis] ; Brett J. Peterson [États-Unis] ; J. Eric Ahlskog [États-Unis] ; Daniel J. Schaid [États-Unis] ; Walter A. Rocca [États-Unis]

Source :

Movement disorders [ 0885-3185 ] ; 2001.

RBID : Pascal:02-0049762

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Hystérectomie, Ménopause, Age apparition, Traitement hormonal, Traitement substitutif, Chimiothérapie, Oestrogène, Facteur risque, Femelle, Adulte.
Wicri :
- topic : Adulte.

English descriptors

KwdEn :
- Adult, Age of onset, Chemotherapy, Estrogen, Female, Hormone replacement therapy, Hysterectomy, Menopause, Parkinson disease, Replacement therapy, Risk factor.

Abstract

We studied the association of Parkinson's disease (PD) with type of menopause (natural or surgical), age at menopause, and postmenopausal estrogen replacement therapy using a case-control design. We used the medical records-linkage system of the Rochester Epidemiology Project to identify 72 women who developed PD in Olmsted County, MN, during the twenty years 1976-1995. Each incident case was matched by age (± I year) to a general population control subject. We collected exposure data through review of the complete medical records of cases and control subjects in the system. PD cases had undergone hysterectomy (with or without unilateral oophorectomy) significantly more often than control subjects (odds ratio [OR] = 3.36: 95% confidence interval [CI] = 1.05-10.77). In addition, PD cases had experienced early menopause (≤ 46 years) more commonly than control subjects (OR = 2.18; 95% CI = 0.88-5.39), Finally, PD cases had used estrogens orally or parenterally for at least 6 months after menopause less frequently (8%) than control subjects (14%; OR = 0.47; 95% CI = 0.12-1.85). However, the findings for early menopause and estrogen replacement therapy were not statistically significant. Despite the limited sample size of this exploratory study, we hypothesize that there is an increased risk of PD in conditions causing an early reduction in endogenous estrogen. This hypothesis needs to be confirmed in a larger study.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 16`
A06				`@2 5`
A08	`01`	`1`	`ENG`	`@1 Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: An exploratory case-control study`
A11	`01`	`1`		`@1 BENEDETTI (Maria D.)`
A11	`02`	`1`		`@1 MARAGANORE (Demetrius M.)`
A11	`03`	`1`		`@1 BOWER (James H.)`
A11	`04`	`1`		`@1 MCDONNELL (Shannon K.)`
A11	`05`	`1`		`@1 PETERSON (Brett J.)`
A11	`06`	`1`		`@1 AHLSKOG (J. Eric)`
A11	`07`	`1`		`@1 SCHAID (Daniel J.)`
A11	`08`	`1`		`@1 ROCCA (Walter A.)`
A14	`01`			`@1 Department of Health Sciences Research, Mayo Clinic and Mayo Foundation @2 Rochester, Minnesota @3 USA @Z 1 aut. @Z 4 aut. @Z 5 aut. @Z 7 aut. @Z 8 aut.`
A14	`02`			`@1 Department of Neurology, Mayo Clinic and Mayo Foundation @2 Rochester, Minnesota @3 USA @Z 2 aut. @Z 3 aut. @Z 6 aut. @Z 8 aut.`
A20				`@1 830-837`
A21				`@1 2001`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000099256460050`
A44				`@0 0000 @1 © 2002 INIST-CNRS. All rights reserved.`
A45				`@0 35 ref.`
A47	`01`	`1`		`@0 02-0049762`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 We studied the association of Parkinson's disease (PD) with type of menopause (natural or surgical), age at menopause, and postmenopausal estrogen replacement therapy using a case-control design. We used the medical records-linkage system of the Rochester Epidemiology Project to identify 72 women who developed PD in Olmsted County, MN, during the twenty years 1976-1995. Each incident case was matched by age (± I year) to a general population control subject. We collected exposure data through review of the complete medical records of cases and control subjects in the system. PD cases had undergone hysterectomy (with or without unilateral oophorectomy) significantly more often than control subjects (odds ratio [OR] = 3.36: 95% confidence interval [CI] = 1.05-10.77). In addition, PD cases had experienced early menopause (≤ 46 years) more commonly than control subjects (OR = 2.18; 95% CI = 0.88-5.39), Finally, PD cases had used estrogens orally or parenterally for at least 6 months after menopause less frequently (8%) than control subjects (14%; OR = 0.47; 95% CI = 0.12-1.85). However, the findings for early menopause and estrogen replacement therapy were not statistically significant. Despite the limited sample size of this exploratory study, we hypothesize that there is an increased risk of PD in conditions causing an early reduction in endogenous estrogen. This hypothesis needs to be confirmed in a larger study.
C02	`01`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Parkinson maladie @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @5 01`
C03	`02`	`X`	`FRE`	`@0 Hystérectomie @5 04`
C03	`02`	`X`	`ENG`	`@0 Hysterectomy @5 04`
C03	`02`	`X`	`SPA`	`@0 Histerectomía @5 04`
C03	`03`	`X`	`FRE`	`@0 Ménopause @5 07`
C03	`03`	`X`	`ENG`	`@0 Menopause @5 07`
C03	`03`	`X`	`SPA`	`@0 Menopausia @5 07`
C03	`04`	`X`	`FRE`	`@0 Age apparition @5 08`
C03	`04`	`X`	`ENG`	`@0 Age of onset @5 08`
C03	`04`	`X`	`SPA`	`@0 Edad aparición @5 08`
C03	`05`	`X`	`FRE`	`@0 Traitement hormonal @5 10`
C03	`05`	`X`	`ENG`	`@0 Hormone replacement therapy @5 10`
C03	`05`	`X`	`SPA`	`@0 Hormonoterapia @5 10`
C03	`06`	`X`	`FRE`	`@0 Traitement substitutif @5 11`
C03	`06`	`X`	`ENG`	`@0 Replacement therapy @5 11`
C03	`06`	`X`	`SPA`	`@0 Tratamiento sustitutivo @5 11`
C03	`07`	`X`	`FRE`	`@0 Chimiothérapie @5 12`
C03	`07`	`X`	`ENG`	`@0 Chemotherapy @5 12`
C03	`07`	`X`	`SPA`	`@0 Quimioterapia @5 12`
C03	`08`	`X`	`FRE`	`@0 Oestrogène @5 13`
C03	`08`	`X`	`ENG`	`@0 Estrogen @5 13`
C03	`08`	`X`	`SPA`	`@0 Estrógeno @5 13`
C03	`09`	`X`	`FRE`	`@0 Facteur risque @5 17`
C03	`09`	`X`	`ENG`	`@0 Risk factor @5 17`
C03	`09`	`X`	`SPA`	`@0 Factor riesgo @5 17`
C03	`10`	`X`	`FRE`	`@0 Femelle @5 20`
C03	`10`	`X`	`ENG`	`@0 Female @5 20`
C03	`10`	`X`	`SPA`	`@0 Hembra @5 20`
C03	`11`	`X`	`FRE`	`@0 Adulte @5 21`
C03	`11`	`X`	`ENG`	`@0 Adult @5 21`
C03	`11`	`X`	`SPA`	`@0 Adulto @5 21`
C07	`01`	`X`	`FRE`	`@0 Homme`
C07	`01`	`X`	`ENG`	`@0 Human`
C07	`01`	`X`	`SPA`	`@0 Hombre`
C07	`02`	`X`	`FRE`	`@0 Système nerveux pathologie @5 37`
C07	`02`	`X`	`ENG`	`@0 Nervous system diseases @5 37`
C07	`02`	`X`	`SPA`	`@0 Sistema nervioso patología @5 37`
C07	`03`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 38`
C07	`03`	`X`	`ENG`	`@0 Central nervous system disease @5 38`
C07	`03`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 38`
C07	`04`	`X`	`FRE`	`@0 Encéphale pathologie @5 39`
C07	`04`	`X`	`ENG`	`@0 Cerebral disorder @5 39`
C07	`04`	`X`	`SPA`	`@0 Encéfalo patología @5 39`
C07	`05`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 40`
C07	`05`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 40`
C07	`05`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 40`
C07	`06`	`X`	`FRE`	`@0 Maladie dégénérative @5 41`
C07	`06`	`X`	`ENG`	`@0 Degenerative disease @5 41`
C07	`06`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 41`
C07	`07`	`X`	`FRE`	`@0 Chirurgie @5 45`
C07	`07`	`X`	`ENG`	`@0 Surgery @5 45`
C07	`07`	`X`	`SPA`	`@0 Cirugía @5 45`
N21				`@1 021`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002937

Links to Exploration step

Pascal:02-0049762

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: An exploratory case-control study</title>
<author><name sortKey="Benedetti, Maria D" sort="Benedetti, Maria D" uniqKey="Benedetti M" first="Maria D." last="Benedetti">Maria D. Benedetti</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Health Sciences Research, Mayo Clinic and Mayo Foundation</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Maraganore, Demetrius M" sort="Maraganore, Demetrius M" uniqKey="Maraganore D" first="Demetrius M." last="Maraganore">Demetrius M. Maraganore</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, Mayo Clinic and Mayo Foundation</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Bower, James H" sort="Bower, James H" uniqKey="Bower J" first="James H." last="Bower">James H. Bower</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, Mayo Clinic and Mayo Foundation</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Mcdonnell, Shannon K" sort="Mcdonnell, Shannon K" uniqKey="Mcdonnell S" first="Shannon K." last="Mcdonnell">Shannon K. Mcdonnell</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Health Sciences Research, Mayo Clinic and Mayo Foundation</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Peterson, Brett J" sort="Peterson, Brett J" uniqKey="Peterson B" first="Brett J." last="Peterson">Brett J. Peterson</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Health Sciences Research, Mayo Clinic and Mayo Foundation</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Ahlskog, J Eric" sort="Ahlskog, J Eric" uniqKey="Ahlskog J" first="J. Eric" last="Ahlskog">J. Eric Ahlskog</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, Mayo Clinic and Mayo Foundation</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Schaid, Daniel J" sort="Schaid, Daniel J" uniqKey="Schaid D" first="Daniel J." last="Schaid">Daniel J. Schaid</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Health Sciences Research, Mayo Clinic and Mayo Foundation</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Rocca, Walter A" sort="Rocca, Walter A" uniqKey="Rocca W" first="Walter A." last="Rocca">Walter A. Rocca</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Health Sciences Research, Mayo Clinic and Mayo Foundation</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, Mayo Clinic and Mayo Foundation</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">02-0049762</idno>
<date when="2001">2001</date>
<idno type="stanalyst">PASCAL 02-0049762 INIST</idno>
<idno type="RBID">Pascal:02-0049762</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002937</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000384</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: An exploratory case-control study</title>
<author><name sortKey="Benedetti, Maria D" sort="Benedetti, Maria D" uniqKey="Benedetti M" first="Maria D." last="Benedetti">Maria D. Benedetti</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Health Sciences Research, Mayo Clinic and Mayo Foundation</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Maraganore, Demetrius M" sort="Maraganore, Demetrius M" uniqKey="Maraganore D" first="Demetrius M." last="Maraganore">Demetrius M. Maraganore</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, Mayo Clinic and Mayo Foundation</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Bower, James H" sort="Bower, James H" uniqKey="Bower J" first="James H." last="Bower">James H. Bower</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, Mayo Clinic and Mayo Foundation</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Mcdonnell, Shannon K" sort="Mcdonnell, Shannon K" uniqKey="Mcdonnell S" first="Shannon K." last="Mcdonnell">Shannon K. Mcdonnell</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Health Sciences Research, Mayo Clinic and Mayo Foundation</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Peterson, Brett J" sort="Peterson, Brett J" uniqKey="Peterson B" first="Brett J." last="Peterson">Brett J. Peterson</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Health Sciences Research, Mayo Clinic and Mayo Foundation</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Ahlskog, J Eric" sort="Ahlskog, J Eric" uniqKey="Ahlskog J" first="J. Eric" last="Ahlskog">J. Eric Ahlskog</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, Mayo Clinic and Mayo Foundation</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Schaid, Daniel J" sort="Schaid, Daniel J" uniqKey="Schaid D" first="Daniel J." last="Schaid">Daniel J. Schaid</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Health Sciences Research, Mayo Clinic and Mayo Foundation</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Rocca, Walter A" sort="Rocca, Walter A" uniqKey="Rocca W" first="Walter A." last="Rocca">Walter A. Rocca</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Health Sciences Research, Mayo Clinic and Mayo Foundation</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, Mayo Clinic and Mayo Foundation</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2001">2001</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Age of onset</term>
<term>Chemotherapy</term>
<term>Estrogen</term>
<term>Female</term>
<term>Hormone replacement therapy</term>
<term>Hysterectomy</term>
<term>Menopause</term>
<term>Parkinson disease</term>
<term>Replacement therapy</term>
<term>Risk factor</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Hystérectomie</term>
<term>Ménopause</term>
<term>Age apparition</term>
<term>Traitement hormonal</term>
<term>Traitement substitutif</term>
<term>Chimiothérapie</term>
<term>Oestrogène</term>
<term>Facteur risque</term>
<term>Femelle</term>
<term>Adulte</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Adulte</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We studied the association of Parkinson's disease (PD) with type of menopause (natural or surgical), age at menopause, and postmenopausal estrogen replacement therapy using a case-control design. We used the medical records-linkage system of the Rochester Epidemiology Project to identify 72 women who developed PD in Olmsted County, MN, during the twenty years 1976-1995. Each incident case was matched by age (± I year) to a general population control subject. We collected exposure data through review of the complete medical records of cases and control subjects in the system. PD cases had undergone hysterectomy (with or without unilateral oophorectomy) significantly more often than control subjects (odds ratio [OR] = 3.36: 95% confidence interval [CI] = 1.05-10.77). In addition, PD cases had experienced early menopause (≤ 46 years) more commonly than control subjects (OR = 2.18; 95% CI = 0.88-5.39), Finally, PD cases had used estrogens orally or parenterally for at least 6 months after menopause less frequently (8%) than control subjects (14%; OR = 0.47; 95% CI = 0.12-1.85). However, the findings for early menopause and estrogen replacement therapy were not statistically significant. Despite the limited sample size of this exploratory study, we hypothesize that there is an increased risk of PD in conditions causing an early reduction in endogenous estrogen. This hypothesis needs to be confirmed in a larger study.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>16</s2>
</fA05>
<fA06><s2>5</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: An exploratory case-control study</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>BENEDETTI (Maria D.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>MARAGANORE (Demetrius M.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>BOWER (James H.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>MCDONNELL (Shannon K.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>PETERSON (Brett J.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>AHLSKOG (J. Eric)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>SCHAID (Daniel J.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>ROCCA (Walter A.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Health Sciences Research, Mayo Clinic and Mayo Foundation</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Neurology, Mayo Clinic and Mayo Foundation</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA20><s1>830-837</s1>
</fA20>
<fA21><s1>2001</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000099256460050</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2002 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>35 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>02-0049762</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>We studied the association of Parkinson's disease (PD) with type of menopause (natural or surgical), age at menopause, and postmenopausal estrogen replacement therapy using a case-control design. We used the medical records-linkage system of the Rochester Epidemiology Project to identify 72 women who developed PD in Olmsted County, MN, during the twenty years 1976-1995. Each incident case was matched by age (± I year) to a general population control subject. We collected exposure data through review of the complete medical records of cases and control subjects in the system. PD cases had undergone hysterectomy (with or without unilateral oophorectomy) significantly more often than control subjects (odds ratio [OR] = 3.36: 95% confidence interval [CI] = 1.05-10.77). In addition, PD cases had experienced early menopause (≤ 46 years) more commonly than control subjects (OR = 2.18; 95% CI = 0.88-5.39), Finally, PD cases had used estrogens orally or parenterally for at least 6 months after menopause less frequently (8%) than control subjects (14%; OR = 0.47; 95% CI = 0.12-1.85). However, the findings for early menopause and estrogen replacement therapy were not statistically significant. Despite the limited sample size of this exploratory study, we hypothesize that there is an increased risk of PD in conditions causing an early reduction in endogenous estrogen. This hypothesis needs to be confirmed in a larger study.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Hystérectomie</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Hysterectomy</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Histerectomía</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Ménopause</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Menopause</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Menopausia</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Age apparition</s0>
<s5>08</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Age of onset</s0>
<s5>08</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Edad aparición</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Traitement hormonal</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Hormone replacement therapy</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Hormonoterapia</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Traitement substitutif</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Replacement therapy</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Tratamiento sustitutivo</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>12</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Oestrogène</s0>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Estrogen</s0>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Estrógeno</s0>
<s5>13</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Facteur risque</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Risk factor</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Factor riesgo</s0>
<s5>17</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Femelle</s0>
<s5>20</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Female</s0>
<s5>20</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Hembra</s0>
<s5>20</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Adulte</s0>
<s5>21</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Adult</s0>
<s5>21</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Adulto</s0>
<s5>21</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Homme</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Human</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Hombre</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Chirurgie</s0>
<s5>45</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Surgery</s0>
<s5>45</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Cirugía</s0>
<s5>45</s5>
</fC07>
<fN21><s1>021</s1>
</fN21>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000384 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000384 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:02-0049762
   |texte=   Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: An exploratory case-control study
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: An exploratory case-control study

Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: An exploratory case-control study

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri